Showing results (111-120 of 192) with videos related to

Sort By:
Pageof 20
Cancer Investigation|September 16, 2024
Efficacy and Safety of First-Line Platinum-Based Doublet Chemotherapy in Advanced Primary Pulmonary Salivary Gland Tumors (PSGTs)Zheng Shi, Xiaohong Zeng, Wei Sun, et al.
Molecular Cancer|August 3, 2022
Targeting KRAS mutant cancers: from druggable therapy to drug resistanceChunxiao Zhu, Xiaoqing Guan, Xinuo Zhang, et al.
Frontiers in Oncology|May 24, 2021
Efficacy and Resistance of Afatinib in Chinese Non-Small Cell Lung Cancer Patients With HER2 Alterations: A Multicenter Retrospective StudyZhengbo Song, Dongqing Lv, Shiqing Chen, et al.
Cancer Medicine|November 16, 2022
The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world studyXiaoqing Yu, Jinfei Si, Jingwen Wei, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|May 24, 2014
[Joint serum tumor markers serve as survival predictive model of erlotinib in the treatment of recurrent non-small cell lung cancer]Lan Shao, Wei Hong, Lei Zheng, et al.
Journal of Chemotherapy (Florence, Italy)|January 23, 2026
Safety analysis of vinorelbine in the real world: a pharmacovigilance study based on the FAERS databaseYuhui Li, Zheng Shi, Xiaoshuang Fu, et al.
Cancer Medicine|June 23, 2023
The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysisYelan Guan, Qifeng Yao, Yue Hao, et al.
Cancer Medicine|November 17, 2022
Analysis of the efficacy and safety of immunotherapy in advanced thymoma patientsYue Hao, Gen Lin, Jing Xiang, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 24, 2024
The influence of PD-L1 expression levels on the efficacy of combination therapy in thymic epithelial tumorsHan Si, Xiaoshuang Fu, Yue Hao, et al.
Lung Cancer (Amsterdam, Netherlands)|March 14, 2021
Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective studyWenxian Wang, Chunwei Xu, Huafei Chen, et al.
Pageof 20